Adeno-associated virus (AAV) production services

Your trusted partner in AAV development and manufacturing

With over two decades of experience, we are industry leaders specializing in a comprehensive array of capabilities for AAV vectors across multiple serotypes.

We’ve manufactured AAV for a total of:

300+ total batches

190+ clinical batches

45+ commercial/PPQ batches

Thermo Fisher Scientific prides itself on cutting-edge capabilities, ensuring the seamless production of AAV vectors with expertise in both natural and novel serotypes. To meet the unique needs of our clients, we employ state-of-the-art technologies using triple transfection in both adherent and suspension cell cultures (mammalian and insect cell lines) as well as producer cell line based viral production and cell line cloning.

Quality assurance: Quality is the cornerstone of our operations. Our rigorous quality assurance measures ensure the production of AAV vectors that meet and exceed regulatory standards, providing you with the utmost confidence in the reliability of our services.
Collaboration opportunities: We believe in the power of collaboration. Thermo Fisher Scientific is eager to explore partnerships and collaborations to drive innovation and advance the field of gene therapy. Let's work together to bring your vision to fruition.
Team expertise: Our team consists of dedicated professionals with diverse expertise in AAV development and manufacturing. From seasoned researchers to skilled technicians, we bring a collective wealth of knowledge to ensure the success of your AAV program.

Our team is experienced in supporting a variety of other viral platforms. For questions about our additional capabilities and capacity, please contact us.

AAV experience with both natural and novel serotypes

AAV natural and novel serotypes experience chart

Helpful Resources

Whitepaper

Evaluating current manufacturing platforms for recombinant AAV production

Realizing the full potential of viral vector-based therapies requires a successful manufacturing platform for recombinant Adeno-associated virus (AAV) vectors.

Blog post

A CDMO Partner for every Gene Therapy Manufacturing Stage

Take a closer look at the experiences of NysnoBio and bluebird bio for insight into what companies need in a CDMO partner for every stage of viral vector manufacturing and development.

Fact sheet

Viral vector development and manufacturing services

Thermo Fisher Scientific provides over 20 years of unparalleled experience in developing and manufacturing viral vector products.

Blog post

Tech transfer process for commercial viral vector manufacturing

Learn how tech transfers can help develop and manufacture viral vectors at scale, accelerate vaccine and gene therapy commercialization, and provide expertise.

Blog post

Regulatory Support for Viral Vector Commercialization

Learn more about the robust viral vector process validation cycle, which includes various assessments and studies to ensure the safety, efficacy, and quality of viral vectors.

Webinar

Benefits of an integrated approach to gene therapy development and manufacturing

Thermo Fisher Scientific's expert will take you through the development and commercialization of viral vectors for gene therapy, so you can navigate these hurdles and deliver the project in a timely, cost-effective manner. With integrated gene therapy development and manufacturing, you can benefit more than a customized solution. It improves coordination, streamlines decision-making, and uses resources more efficiently.

Strategies to accelerate drug development through harmonization of early and late stage processes

This technical article presents a harmonized and streamlined approach established at Thermo Fisher Scientific for manufacturing AAV and LV vectors for discovery research using technologies and processes mirroring current GMP platforms.

Presentation

Preparing viral vector productions for commercialization

Gene therapy vectors are rapidly approaching the commercial space so commercial readiness is critical for success. Watch our webinar to learn about our capabilities and approaches for preparing viral vectors for commercialization.

Infographic

Regulatory pathways for CGT and ATMP products

CGT is one of the world's fastest-growing therapeutic areas today. Instead of treating patients for the rest of their lives, these therapies offer them hope of a cure. In this infographic, we will review three tips for achieving regulatory success.

eBook

Cell Therapy Logistics Advanced Therapy

In this eBook we share the five key differences in the drug development and review process for companies hoping to gain market access through US Food and Drug Administration (FDA) or European Medicines Agency (EMA) approval—as well as tips for navigating these differences.

Ready to discuss your project?

Connect with us